Table 3 Nonhaematological toxicity (drug-relateda)

From: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

  

Maximum grade of toxicity per patient

  

Nausea and/or vomiting

Venous pain

Malaise

Hyper- or hypotension

Flushing/sweating

Acute neuro symptoms

Dyspnoea

Dose (mg m−2)

No. of patients

1–2

3–4

1–2

3–4

1–2

3–4

1–2

3–4

1–2

3–4

1–2

3–4

1–2

3–4

6

3

1

    

1

  

1

     

10.2

3

1

    

1

        

20.4

3

1

   

2

         

40.8

3

              

81.6

3

1

     

1

      

1

160

3

1

 

1

     

1

     

240

3

1

 

1

           

360

3

  

2

     

1

     

500

6

1

 

2

 

1

 

2

 

1

     

650

3

2

 

1

          

1

850

3

  

2

   

1

       

1100

3

2

 

3

 

1

 

3

      

1

1375

3

  

3

   

1

   

2

   

1650

3

3

 

1

 

2

 

1

   

2

   

2000

3

2

 

2

   

1

 

1

 

3

   

2600

3

 

2

2

 

1

 

2

 

3

 

3

  

1

3100

3

3

 

2

   

2

 

3

 

3

  

1

3700

7

6

 

6

   

6

 

7

 

7

  

2

4900

3

3

 

3

   

3

 

3

  

3

 

1

  1. aAlmost certainly, probably or possibly related to DMXAA. Neuro=neurological.